Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Primary listing
Employees
15,182
Headquarters
Website
Regeneron Metrics
BasicAdvanced
$68B
15.73
$41.59
-
$2.64
0.54%
Price and volume
Market cap
$68B
52-week high
$923.75
52-week low
$476.49
Average daily volume
1.1M
Dividend rate
$2.64
Financial strength
Current ratio
4.82
Quick ratio
4.253
Long term debt to equity
8.739
Total debt to equity
8.739
Interest coverage (TTM)
91.71%
Profitability
EBITDA (TTM)
4,392.5
Gross margin (TTM)
49.37%
Net profit margin (TTM)
32.13%
Operating margin (TTM)
27.10%
Effective tax rate (TTM)
11.02%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
6.22%
Return on equity (TTM)
15.19%
Valuation
Price to earnings (TTM)
15.735
Price to revenue (TTM)
4.857
Price to book
2.19
Price to tangible book (TTM)
2.29
Dividend yield (TTM)
0.40%
Forward dividend yield
0.54%
Growth
Revenue change (TTM)
2.89%
Earnings per share change (TTM)
2.88%
3-year revenue growth (CAGR)
1.29%
10-year revenue growth (CAGR)
14.11%
3-year earnings per share growth (CAGR)
-4.26%
10-year earnings per share growth (CAGR)
23.66%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Bulls say / Bears say
Dupixent global net sales increased 22% to $4.34 billion in Q2 2025, surpassing analyst estimates and underscoring robust demand for its immunology franchise. (Reuters)
Regeneron’s oncology segment saw Libtayo sales outpace expectations, reaching $377 million versus a forecast of $338.75 million, highlighting strong growth momentum in skin cancer and NSCLC indications. (Reuters)
The FDA granted accelerated approval for Lynozyfic (linvoseltamab) in relapsed or refractory multiple myeloma, marking Regeneron’s first BCMA×CD3 bispecific approval and bolstering its late-stage oncology pipeline. (Reuters)
U.S. net sales of EYLEA fell 25% year-over-year to $1.15 billion in Q2 2025 amid mounting biosimilar pressure and competition from Roche’s Vabysmo. (Reuters)
The FDA twice declined approval for Regeneron’s odronextamab blood cancer therapy due to manufacturing site inspection issues at Catalent, a setback that also delayed three pending EYLEA HD applications. (Reuters)
Amgen’s biosimilar Pavblu will enter the U.S. market after a court decision lifted an injunction, intensifying competition and pricing pressure on Regeneron’s EYLEA franchise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $68B as of October 30, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 15.73 as of October 30, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of October 30, 2025, the dividend rate is $2.64 and the yield is 0.54%. Regeneron has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment is scheduled for December 05, 2025.
What is the beta indicator for Regeneron?
Regeneron (REGN) does not currently have a Beta indicator.